RT Journal Article
SR Electronic
T1 Rapid, accurate, nucleobase detection using FnCas9
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.13.20193581
DO 10.1101/2020.09.13.20193581
A1 Mohd. Azhar
A1 Rhythm Phutela
A1 Manoj Kumar
A1 Asgar Hussain Ansari
A1 Riya Rauthan
A1 Sneha Gulati
A1 Namrata Sharma
A1 Dipanjali Sinha
A1 Saumya Sharma
A1 Sunaina Singh
A1 Sundaram Acharya
A1 Deepanjan Paul
A1 Poorti Kathpalia
A1 Meghali Aich
A1 Paras Sehgal
A1 Gyan Ranjan
A1 Rahul C. Bhoyar
A1 Indian CoV2 Genomics & Genetic Epidemiology (IndiCovGEN) Consortium
A1 Khushboo Singhal
A1 Harsha Lad
A1 Pradeep Kumar Patra
A1 Govind Makharia
A1 Giriraj Ratan Chandak
A1 Bala Pesala
A1 Debojyoti Chakraborty
A1 Souvik Maiti
YR 2020
UL http://medrxiv.org/content/early/2020/09/14/2020.09.13.20193581.abstract
AB Rapid detection of pathogenic sequences or variants in DNA and RNA through a point-of-care diagnostic approach is valuable for accelerated clinical prognosis as has been witnessed during the recent COVID-19 outbreak. Traditional methods relying on qPCR or sequencing are difficult to implement in settings with limited resources necessitating the development of accurate alternative testing strategies that perform robustly. Here, we present FnCas9 Editor Linked Uniform Detection Assay (FELUDA) that employs a direct Cas9 based enzymatic readout for detecting nucleotide sequences and identifying nucleobase identity without the requirement of trans-cleavage activity of reporter molecules. We demonstrate that FELUDA is 100% accurate in detecting single nucleotide variants (SNVs) including heterozygous carriers of a mutation and present a simple design strategy in the form of a web-tool, JATAYU, for its implementation. FELUDA is semi quantitative, can be adapted to multiple signal detection platforms and can be quickly designed and deployed for versatile applications such as infectious disease outbreaks like COVID-19. Using a lateral flow readout within 1h, FELUDA shows 100% sensitivity and 97% specificity across all range of viral loads in clinical samples. In combination with RT-RPA and a smartphone application True Outcome Predicted via Strip Evaluation (TOPSE), we present a prototype for FELUDA for CoV-2 detection at home.Single sentence summary A method to identify nucleotide sequence or nucleobase identity using FnCas9 and its implementation in the rapid and accurate diagnosis of SARS-CoV-2Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by CSIR Sickle Cell Anemia Mission (HCP0008), TATA Steel CSR (SSP2001) and a Lady Tata Young Investigator award (GAP0198) to D.C.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Ethics Committee of CSIR IGIBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript can be obtained by mailing to debojyoti.chakraborty@igib.in